Invesco
PRME icon

Invesco’s Prime Medicine PRME Stock Holding History

Invesco’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$337K Buy
96,875
+40,096
+71% +$153K ﹤0.01% 3298
2025
Q4 		$197K Sell
56,779
-705,299
-93% -$3.14M ﹤0.01% 3533
2025
Q3 		$4.22M Buy
762,078
+748,416
+5,478% +$3.04M ﹤0.01% 2308
2025
Q2 		$33.7K Sell
13,662
-1,174
-8% -$1.81K ﹤0.01% 3743
2025
Q1 		$29.5K Sell
14,836
-235
-2% -$599 ﹤0.01% 3729
2024
Q4 		$44K Buy
15,071
+1,048
+7% +$3.68K ﹤0.01% 3703
2024
Q3 		$54.3K Buy
14,023
+586
+4% +$2.71K ﹤0.01% 3676
2024
Q2 		$69.1K Buy
13,437
+2,826
+27% +$17.1K ﹤0.01% 3790
2024
Q1 		$74.3K Buy
+10,611
New +$80.5K ﹤0.01% 3768

Other funds holding PRME

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Invesco's PRME Position: Q1 2026 in Review

Invesco increased its Prime Medicine (PRME) stake by 71% in Q1 2026, buying an estimated $153K and bringing the position to 96,875 shares worth $337K. The position accounts for ﹤0.01% of the portfolio, ranked #3298.

Invesco first reported a position in PRME in Q1 2024 and has held it in 9 quarters since. The position peaked at $4.22M in Q3 2025. 192 funds tracked by Wall St. Rank hold PRME as of Q1 2026.

  • Invesco held 96,875 shares of Prime Medicine worth $337K as of Q1 2026.
  • Invesco bought 40,096 Prime Medicine shares in Q1 2026, an estimated $153K.
  • Prime Medicine made up ﹤0.01% of Invesco's portfolio in Q1 2026, its #3298 holding.
  • Invesco first reported a position in Prime Medicine in Q1 2024 and has held it in 9 quarters since.
  • Invesco's Prime Medicine position peaked at $4.22M in Q3 2025.
  • 192 funds tracked by Wall St. Rank held Prime Medicine as of Q1 2026.

Based on Invesco's 13F filing for Q1 2026, filed 12 May 2026.